ACTRN12624000935538尚未招募1 期
A Single-Arm Comparative Imaging study to evaluate the uptake of 68Ga-NTA-476 on PET/CT Compared to Standard of Care 18F-DCFPyL PET/CT in Men with Prostate Cancer
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Diagnosis
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- Male
入选标准
- •1. Willing and able to provide informed consent prior to start of any study procedures and assessments and must be willing to comply with all study procedures.
- •2. Adult participants greater than or equal to 18 years of age.
- •3. Participants with a documented history of histologically confirmed diagnosis of prostate cancer.
- •o Participants must have PSA > 0.1 ng/mL.
- •o Participants on chemotherapy may be approved on a case-by-case basis at the principal investigator's discretion if the last dose of chemotherapy is administered at least 3 weeks prior to receipt of 68Ga-NTA-476, and subsequent dose of chemotherapy are to resume following completion of End of Treatment Visit (EOTV), if it is determined not to put the patient at an increased risk of adverse drug effects and/or interfere with the integrity of study outcome.
- •o Participants on other anti-cancer therapy, such as novel anti-androgen therapy, may be allowed on a case-by-case basis at the principal investigator's discretion, with an agreement of a washout period prior to 68Ga-NTA-476 dosing, if it is determined not to put the patient at an increased risk of adverse drug effects and/or interfere with the integrity of study outcome.
- •4. Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2.
- •5. Participants must have a life expectancy of >3 months in the opinion of the Investigator.
- •6. Male participants who are able to father a child must agree to avoid impregnating a partner and to adhere to a highly effective method of contraception during the study and for 14 days after the last injection of 68Ga-NTA-476. Participants must agree to not donate sperm during the study and for 14 days after the injection of 68Ga-NTA-476. Acceptable methods of contraception include a condom in conjunction with hormonal contraception, a vaginal ring or intrauterine device (IUD), or documented evidence of surgical sterilisation. Confirmed absence of sperm in the ejaculate is also acceptable.
排除标准
- •7. Have any medical condition that would, in the Investigator’s judgment, prevent the participant’s full participation in the clinical study due to safety concerns or compliance with clinical study procedures, including but not limited to participants with severe claustrophobia.
- •8. Residual toxicity > Grade 1 from prior/current anti-cancer therapy (except alopecia). Participants with > Grade 1 toxicity from prior anti-cancer therapy may be approved on a case-by-case basis at the principal investigator's discretion, if it is determined not to put the patient at an increased risk of adverse drug effects and/or interfere with the integrity of study outcome.
- •9. History of uncontrolled allergic reactions and/or known or expected hypersensitivity to peptide therapeutics, including 68Ga-NTA-476 or any of its excipients.
- •10. Inadequate organ functions as reflected in laboratory parameters:
- •o Creatinine clearance (calculated using Cockcroft-Gault formula, or measured) < 60 mL/min or serum creatinine >1.5 x upper limit of normal (ULN)
- •o Platelet count of < 75 x 109/L
- •o Absolute neutrophil count (ANC) < 1.0 x 109/L
- •o Haemoglobin < 9 g/dL
- •o Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 3 x ULN, or > 5 x ULN for patients with known liver metastases
- •o Total bilirubin > 1.5 x ULN, except for patients with documented Gilbert’s syndrome who are eligible if total bilirubin is less than or equal to 3 x ULN
- •11. For participants not taking warfarin or other anticoagulants: international normalised ratio (INR) less than or equal to 1.5 or prothrombin time (PT) less than or equal to 1.5 x ULN; and either partial thromboplastin time or activated partial thromboplastin time (PTT or aPTT) less than or equal to 1.5 x ULN. Participants taking warfarin must be on a stable dose that results in a stable INR <3.5. Among participants receiving other anticoagulant therapy, PT or aPTT must be within the intended therapeutic range of the anticoagulant.
- •12. Major surgery within 28 days prior to the dose of 68Ga-NTA-476. Exceptions may be approved on a case-by-case basis at the principal investigator's discretion, if it is determined not to put the participant at an increased risk of adverse drug effects and/or interfere with the integrity of study outcome.
- •13. Any uncontrolled intercurrent illness or clinically significant uncontrolled condition(s), including but not limited to active bacterial, fungal, or viral infections requiring systemic therapy.
研究者
相似试验
尚未招募
不适用
Study that compares Prostate Volume Measured by the ProstaMetrix System with Ultrasound.CTRI/2021/09/036602MedicaMetrix Devices Pvt Ltd
尚未招募
2 期
Pre And Post Clinical Study To Evaluate The Effect Of External Application Of Kusumbha Taila In The Management Of HirsutismCTRI/2024/07/070930Dr Ahana Salim
招募中
2 期
study held to see the effect of local application of alkaline powder of saptaparna plant in haemorrhoidsCTRI/2021/11/038000Ishan parashar
尚未招募
2 期
Management of akala palitya by using Japapushpa ras nasya.CTRI/2023/07/055472Shruti Ashok Kumar Shukla
尚未招募
不适用
A study to check the bioavailability of one drug compare to the other drug in healthy volunteers.CTRI/2014/08/004897Akay Flavours Aromatics PvtLtd50